Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05295992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05295992 · ClinicalTrials.gov record · last posted 2026-03-06

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

Study acronym: ARTIA-Vesica
StatusActive, Not Recruiting
PhaseNot applicable
Started2022-03-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2022-03-15; most recent amendment 2026-03-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-04
Status change Recruiting→Active, Not Recruitingv4
2022-06-29
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05295992
Lead Sponsor Varian, a Siemens Healthineers Company
Collaborators: Herlev Hospital, Rigshospitalet, Denmark
Conditions Muscle-Invasive Bladder Carcinoma
Enrollment 110 participants
Start Date 2022-03-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-06